Literature DB >> 459247

beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man.

R L Galeazzi, M Gugger, P Weidmann.   

Abstract

Cardiac and renal effects (measured as the reduction in exercise-induced tachycardia and PRA, respectively) and circulating drug concentrations after acute beta blockade with intravenous pindolol were compared between seven normal volunteers and six patients with terminal renal failure. Kinetic parameters were similar in both groups (total body clearance, 450 mg/min), indicating enhanced extrarenal elimination in patients. For any given drug concentration, however, the uremic patients responded to beta blockade with a greater decrease in pulse rate than did normal volunteers (P less than 0.001). Moreover, in the same group, the decrease of PRA was more marked (from 13.3 to 5.7 vs. 3.3 to 1.9 ng/ml/hr) and lasted longer (8 hours and more vs. 2 hours). Plasma aldosterone remained unchanged. These data reveal an increased dependency of both heart rate and renin release on beta adrenergic-mediated mechanisms in uremic man. They also show that kinetic findings in normal subjects cannot always be extrapolated to predict kinetic behavior in disease, and that similar kinetics do not imply similar effectiveness.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 459247     DOI: 10.1038/ki.1979.86

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

Authors:  J van Harten; J Burggraaf; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 5.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

6.  Metabolism of pindolol in patients with renal failure.

Authors:  E E Ohnhaus; H Heidemann; J Meier; G Maurer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 8.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

9.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

10.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.